Clinical Trial Update: A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating the safety and pharmacokinetics of the oral agent GSK1363089 (XL880) in subjects with solid tumors; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK1363089 (XL880) (GSK1363089)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED